The high rates of attrition that occur in drug development are widely regarded as problematic, but the failure of well-designed studies benefits both researchers and healthcare systems by, for example, generating evidence about disease theories and demonstrating the limits of proven drugs. A wider recognition of these benefits will help the biomedical research enterprise to take full advantage of all the information generated during the drug development process.
History
Publisher Statement
Copyright London and Kimmelman.
This article is distributed under the
terms of the Creative Commons
Attribution License, which permits
unrestricted use and redistribution
provided that the original author and
source are credited